- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
SMS Lifesciences India Limited has announced a board meeting for approving the financial results for the quarter and half-year.
In a recent rating action, Infomerics Valuation and Rating Limited has assigned ratings to SMS Lifesciences and its material subsidiary, Mahi Drugs Private Limited. SMS Lifesciences has received a long-term rating of IVR BBB with a positive outlook and a short-term rating of IVR A3+. The company’s total bank facilities amount to ₹81.86 crore (Cr). The rating reflects the consolidated financial profile of SMS Lifesciences and Mahi Drugs, underpinned by common management and significant operational linkages.
The assigned ratings indicate a stable financial health with low to moderate credit risk. This could potentially influence the company’s borrowing costs favorably, enhancing investor confidence, particularly in the context of possible revenue stability and operational efficiency within the life sciences sector.
Investor Insight: Given the positive ratings and the strategic direction indicated, the stock may present a valuable opportunity for investors looking for exposure in the pharmaceutical sector.